EF Hutton Initiates Coverage On Lumos Pharma With Buy Rating, Announces Price Target of $16
EF Hutton Initiates Coverage On Lumos Pharma With Buy Rating, Announces Price Target of $16
EF霍頓開始覆蓋lumos pharma,並給出買入評級,公佈目標股價爲16美元
EF Hutton analyst Jason Kolbert initiates coverage on Lumos Pharma (NASDAQ:LUMO) with a Buy rating and announces Price Target of $16.
EF Hutton 的分析師Jason Kolbert開始覆蓋lumos pharma(納斯達克:LUMO),買入評級,並公佈目標股價爲16美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。